Cocrystal Pharma (COCP) vs Estrella Immunopharma (ESLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed Estrella Immunopharma (ESLA) over the past year, losing 14.4% versus a loss of 67.9%. Over five years, COCP leads with a -90.5% price change compared with -95.8% for ESLA. Cocrystal Pharma is the larger company by market cap ($20.5 million vs $17.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COCP | ESLA |
|---|---|---|
| Share price | $1.07 | $0.3904 |
| Market cap | $20.52M | $16.98M |
| 1-day change | -0.47% | -6.49% |
| YTD return | +9.18% | -73.24% |
| 1-year return | -14.40% | -67.88% |
| 5-year return | -90.51% | -95.77% |
| EPS (TTM) | $-0.76 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.03 | $3.15 |
| 52-week low | $0.76 | $0.3083 |
| Distance from 52-week high | -47.54% | -87.61% |
| Analyst consensus | none | none |
| Avg. price target upside | +745.07% | +2973.77% |
| Average volume | 56.00K | 38.61K |
| Shares outstanding | 19.26M | 43.50M |
| Employees | 10 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed ESLA by 53.5 percentage points over the past year.
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
COCP vs ESLA FAQ
Which is bigger, Cocrystal Pharma or Estrella Immunopharma?
Cocrystal Pharma (COCP) is larger, with a market capitalization of $20.52M compared with $16.98M for Estrella Immunopharma (ESLA).
Which stock has performed better over the past year, COCP or ESLA?
COCP returned -14.40% over the past 12 months, compared with -67.88% for ESLA (price return, excluding dividends). Past performance does not predict future results.
Are Cocrystal Pharma and Estrella Immunopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Cocrystal Pharma and Biotechnology: Biological Products (No Diagnostic Substances) for Estrella Immunopharma.